Literature DB >> 30571927

Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells.

Laurence Booth1, Jane L Roberts1, Cindy Sander2, Alshad S Lalani3, John M Kirkwood2, John F Hancock4, Andrew Poklepovic5, Paul Dent1.   

Abstract

There is no efficacious standard of care therapy for uveal melanoma. Unlike cutaneous disease, uveal melanoma does not exhibit RAS mutations but instead contains mutations with ~90% penetrance in either Gαq or Gα11. Previously we demonstrated that neratinib caused ERBB1/2/4 and RAS internalization into autolysosomes which resulted in their proteolytic degradation. In PDX isolates of uveal melanoma, neratinib caused the internalization and degradation of Gαq and Gα11 in parallel with ERBB1 breakdown. These effects were enhanced by the HDAC inhibitor entinostat. Similar data were obtained using GFP/RFP tagged forms of K-RAS V12. Down regulation of Gαq and Gα11 expression and RAS-GFP/RFP fluorescence required Beclin1 and ATG5. The [neratinib + entinostat] combination engaged multiple pathways to mediate killing. One was from ROS-dependent activation of ATM via AMPK-ULK1-ATG13-Beclin1/ATG5. Another pathway was from CD95 via caspase 8-RIP1/RIP3. A third was from reduced expression of HSP70, HSP90, HDAC6 and phosphorylation of eIF2α. Downstream of the mitochondrion both caspase 9 and AIF played roles in tumor cell execution. Knock down of ATM/AMPK/ULK-1 prevented ATG13 phosphorylation and degradation of RAS and Gα proteins. Over-expression of activated mTOR prevented ATG13 phosphorylation and suppressed killing. Knock down of eIF2α maintained BCL-XL and MCL-1 expression. Within 6h, [neratinib + entinostat] reduced the expression of the immunology biomarkers PD-L1, ODC, IDO-1 and enhanced MHCA levels. Our data demonstrate that [neratinib + entinostat] down-regulates oncogenic RAS and the two key oncogenic drivers present in most uveal melanoma patients and causes a multifactorial form of killing via mitochondrial dysfunction and toxic autophagy. Abbreviations: ERK: extracellular regulated kinase; PI3K: phosphatidyl inositol 3 kinase; ca: constitutively active; dn: dominant negative; ER: endoplasmic reticulum; AIF: apoptosis inducing factor; AMPK: AMP-dependent protein kinase; mTOR: mammalian target of rapamycin; JAK: Janus Kinase; STAT: Signal Transducers and Activators of Transcription; MAPK: mitogen activated protein kinase; PTEN: phosphatase and tensin homologue on chromosome ten; ROS: reactive oxygen species; CMV: empty vector plasmid or virus; si: small interfering; SCR: scrambled; IP: immunoprecipitation; VEH: vehicle; HDAC: histone deacetylase.

Entities:  

Keywords:  G alpha; HDAC inhibitor; RAS; autophagy; neratinib

Mesh:

Substances:

Year:  2018        PMID: 30571927      PMCID: PMC6606002          DOI: 10.1080/15384047.2018.1551747

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  44 in total

Review 1.  Targeting autophagy in cancer.

Authors:  Jean M Mulcahy Levy; Christina G Towers; Andrew Thorburn
Journal:  Nat Rev Cancer       Date:  2017-07-28       Impact factor: 60.716

2.  RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.

Authors:  Xu Chen; Qiuxia Wu; Philippe Depeille; Peirong Chen; Sophie Thornton; Helen Kalirai; Sarah E Coupland; Jeroen P Roose; Boris C Bastian
Journal:  Cancer Cell       Date:  2017-05-08       Impact factor: 31.743

3.  Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.

Authors:  Adly Yacoub; William Hawkins; David Hanna; Hong Young; Margaret A Park; Mark Grant; John D Roberts; David T Curiel; Paul B Fisher; Kristoffer Valerie; Steven Grant; Michael P Hagan; Paul Dent
Journal:  Mol Pharmacol       Date:  2006-10-18       Impact factor: 4.436

4.  Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma.

Authors:  Hanyin Cheng; Vivian Chua; Connie Liao; Timothy J Purwin; Mizue Terai; Ken Kageyama; Michael A Davies; Takami Sato; Andrew E Aplin
Journal:  Mol Cancer Ther       Date:  2017-01-30       Impact factor: 6.261

5.  Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1.

Authors:  Durga N Tripathi; Rajdeep Chowdhury; Laura J Trudel; Andrew R Tee; Rebecca S Slack; Cheryl Lyn Walker; Gerald N Wogan
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-22       Impact factor: 11.205

6.  Oncogenic mutations in GNAQ occur early in uveal melanoma.

Authors:  Michael D Onken; Lori A Worley; Meghan D Long; Shenghui Duan; M Laurin Council; Anne M Bowcock; J William Harbour
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-08-21       Impact factor: 4.799

Review 7.  How much do we know about the coupling of G-proteins to serotonin receptors?

Authors:  Matteo Giulietti; Viviana Vivenzio; Francesco Piva; Giovanni Principato; Cesario Bellantuono; Bernardo Nardi
Journal:  Mol Brain       Date:  2014-07-10       Impact factor: 4.041

8.  Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism.

Authors:  Krushna C Patra; Yasutaka Kato; Yusuke Mizukami; Sebastian Widholz; Myriam Boukhali; Iulia Revenco; Elizabeth A Grossman; Fei Ji; Ruslan I Sadreyev; Andrew S Liss; Robert A Screaton; Kei Sakamoto; David P Ryan; Mari Mino-Kenudson; Carlos Fernandez-Del Castillo; Daniel K Nomura; Wilhelm Haas; Nabeel Bardeesy
Journal:  Nat Cell Biol       Date:  2018-06-25       Impact factor: 28.824

9.  Patient survival in uveal melanoma is not affected by oncogenic mutations in GNAQ and GNA11.

Authors:  A E Koopmans; J Vaarwater; D Paridaens; N C Naus; E Kilic; A de Klein
Journal:  Br J Cancer       Date:  2013-06-18       Impact factor: 7.640

10.  HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo.

Authors:  Laurence Booth; Jane L Roberts; Andrew Poklepovic; Francesca Avogadri-Connors; Richard E Cutler; Alshad S Lalani; Paul Dent
Journal:  Oncotarget       Date:  2017-10-09
View more
  10 in total

Review 1.  The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib.

Authors:  Laurence A Booth; Jane L Roberts; Paul Dent
Journal:  Semin Cancer Biol       Date:  2019-10-20       Impact factor: 15.707

Review 2.  Recent Advances and Challenges in Uveal Melanoma Immunotherapy.

Authors:  Yihang Fu; Wei Xiao; Yuxiang Mao
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

3.  Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway.

Authors:  John M Idso; Shunhua Lao; Nathan J Schloemer; Jeffrey Knipstein; Robert Burns; Monica S Thakar; Subramaniam Malarkannan
Journal:  Oncotarget       Date:  2020-05-19

4.  Contribution of the STAT Family of Transcription Factors to the Expression of the Serotonin 2B (HTR2B) Receptor in Human Uveal Melanoma.

Authors:  Manel Benhassine; Gaëtan Le-Bel; Sylvain L Guérin
Journal:  Int J Mol Sci       Date:  2022-01-29       Impact factor: 5.923

Review 5.  Kinase inhibitors: look beyond the label on the bottle.

Authors:  Paul Dent; Andrew Poklepovic; Laurence Booth; John F Hancock
Journal:  Cancer Drug Resist       Date:  2019-12-19

6.  The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.

Authors:  Wenying Shu; Xue Zhu; Ke Wang; Svetlana Cherepanoff; R Max Conway; Michele C Madigan; Hong Zhu; Ling Zhu; Michael Murray; Fanfan Zhou
Journal:  Cell Oncol (Dordr)       Date:  2022-07-04       Impact factor: 7.051

Review 7.  Advanced Acral Melanoma Therapies: Current Status and Future Directions.

Authors:  Yiqun Zhang; Shijie Lan; Di Wu
Journal:  Curr Treat Options Oncol       Date:  2022-09-20

Review 8.  Epigenetic Control of Autophagy in Cancer Cells: A Key Process for Cancer-Related Phenotypes.

Authors:  Paul Peixoto; Céline Grandvallet; Jean-Paul Feugeas; Michaël Guittaut; Eric Hervouet
Journal:  Cells       Date:  2019-12-17       Impact factor: 6.600

9.  Metabolism of Histone Deacetylase Proteins Opsonizes Tumor Cells to Checkpoint Inhibitory Immunotherapies.

Authors:  Paul Dent; Laurence Booth; Andrew Poklepovic
Journal:  Immunometabolism       Date:  2019-12-04

10.  Inhibition of heat shock proteins increases autophagosome formation, and reduces the expression of APP, Tau, SOD1 G93A and TDP-43.

Authors:  Paul Dent; Laurence Booth; Jane L Roberts; Andrew Poklepovic; Derek Cridebring; Eric M Reiman
Journal:  Aging (Albany NY)       Date:  2021-07-12       Impact factor: 5.682

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.